# M23-385 (ABBV-706): what clinicians are saying

> 69 statements from 20 sources (1 video, 17 posts, 1 paper, 1 registry record), 37 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026.

## Report

- Trial: A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
- NCT ID: NCT05599984
- Registry: https://clinicaltrials.gov/study/NCT05599984
- Sponsor: AbbVie
- Phase: Phase 1
- Status: Active, not recruiting
- Drugs tested: ABBV-706; ABBV-706 plus budigalimab; ABBV-706 plus platinum-based chemotherapy
- Indication: advanced solid tumors
- Version: v1.0.0, edition 1
- Accepted: 2026-11-21 UTC
- Last checked: 2026-11-21 UTC
- Release hash: 21cac369df7eb44e4b8f174c14ed6d20f1ba9e2de857fac29ed20c0e0b02be61

## Counts

- Commentary sources screened: 29
- Sources cited by verified statements: 20
- Verified statements: 69
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 37
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 14
- Speakers cited: 14
- Cited speakers with a verified identity: 14
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 11
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 11
- By role and specialty (the abstract's specialty counts):
  - 7 physician, Medical oncology
  - 4 physician, specialty not confirmed

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist supports further study of M23-385 because of responses despite platinum resistance, but their pulmonary reassurance applies only to the budigalimab combination. Fatal treatment-related pneumonitis was reported with monotherapy; these accounts do not demonstrate disagreement within the same cohort. Another medical oncologist qualifies their favorable reading by stressing small cohorts. Survival observations remain preliminary, and neither budigalimab’s added benefit nor benefit after tarlatamab is established.

## Question clinicians left open

What do clinicians still need to see in larger cohorts to assess severe hematologic toxicity and pneumonitis/ILD risk with ABBV-706 monotherapy and its combination with budigalimab in relapsed/refractory SCLC?

From finding F1 (8 statements from 3 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. ABBV-706: most clinicians highlight safety with budigalimab; one relays deaths
  - 8 statements from 3 speakers in 4 sources, 1 of them a podcast or video.
  - 2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of the 3 holds its caveat, “one relays deaths”.
  - 3 of the report's 11 cited clinicians.
- F2. ABBV-706 alone: most speakers highlight ORR, but some clinicians flag small numbers
  - 14 statements from 6 speakers in 9 sources, 1 of them a podcast or video.
  - 5 of the 6 named speakers in this finding hold this view; 2 of them hold its caveat, “some clinicians flag small numbers”.
  - 5 of the report's 11 cited clinicians.
- F3. ABBV-706 monotherapy dose: how a clinician frames the efficacy–safety balance
  - 10 statements from 2 speakers in 5 sources, 1 of them a podcast or video.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 2 of the report's 11 cited clinicians.
- F4. ABBV-706 + budigalimab: what speakers say
  - 7 statements from 3 speakers in 4 sources, 1 of them a podcast or video.
  - 3 of the report's 11 cited clinicians.
- F5. Subtype and prior Cisplatin: what a speaker asks; a clinician notes a ctDNA link
  - 6 statements from 3 speakers in 5 sources.
  - 1 of the 3 named speakers in this finding holds this view; 1 of the 3 holds its caveat, “a clinician notes a ctDNA link”.
  - 2 of the report's 11 cited clinicians.
- F6. Other NENs: what clinicians highlight in early ABBV-706 activity and unmet need
  - 7 statements from 3 speakers in 4 sources, 1 of them a podcast or video.
  - 3 of the 3 named speakers in this finding hold this view, each a confirmed clinician.
  - 3 of the report's 11 cited clinicians.
- F7. ABBV-706: a clinician seeks larger trials; one sees scope if tarlatamab fails
  - 5 statements from 2 speakers in 3 sources, 1 of them a podcast or video.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one sees scope if tarlatamab fails”.
  - 2 of the report's 11 cited clinicians.
- F8. SEZ6: why most speakers welcome development; some clinicians welcome the phase 1 paper
  - 9 statements from 6 speakers in 7 sources, 1 of them a podcast or video.
  - 4 of the 6 named speakers in this finding hold this view; 2 of the 6 hold its caveat, “some clinicians welcome the phase 1 paper”.
  - 5 of the report's 11 cited clinicians.
- F9. ABBV-706 trials: why a clinician links future access to local SCLC burden
  - 4 statements from 1 speaker in 3 sources, 1 of them a podcast or video.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 11 cited clinicians.

### Beyond the trial population

- F10. Symptomatic brain metastases: why a clinician favors RT/WBRT over tarlatamab
  - 2 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 11 cited clinicians.

1 of the 10 findings and 2 of the 69 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 8 | 6 | 4 | 3 | 4 |
| F2 | 14 | 15 | 9 | 6 | 3 |
| F3 | 10 | 9 | 5 | 2 | 3 |
| F4 | 7 | 6 | 4 | 3 | 3 |
| F5 | 6 | 5 | 5 | 3 | 3 |
| F6 | 7 | 7 | 4 | 3 | 3 |
| F7 | 5 | 4 | 3 | 2 | 2 |
| F8 | 9 | 8 | 7 | 6 | 3 |
| F9 | 4 | 4 | 3 | 1 | 3 |
| F10 | 2 | 2 | 2 | 1 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 4 | 0 | 0 | 0 | 4 | 8 | 0 | 2 posts and articles, 1 podcast or video, 1 publication |
| F2 | 7 | 0 | 1 | 0 | 6 | 17 | 2 | 7 posts and articles, 1 podcast or video, 1 publication |
| F3 | 4 | 0 | 0 | 0 | 6 | 12 | 0 | 3 posts and articles, 1 podcast or video, 1 publication |
| F4 | 5 | 0 | 0 | 0 | 2 | 8 | 0 | 2 posts and articles, 1 podcast or video, 1 publication |
| F5 | 2 | 2 | 0 | 0 | 2 | 7 | 1 | 4 posts and articles, 1 publication |
| F6 | 5 | 0 | 1 | 1 | 0 | 8 | 1 | 3 posts and articles, 1 podcast or video |
| F7 | 3 | 0 | 0 | 1 | 1 | 5 | 0 | 1 post or article, 1 podcast or video, 1 publication |
| F8 | 7 | 0 | 1 | 0 | 1 | 11 | 0 | 5 posts and articles, 1 podcast or video, 1 publication |
| F9 | 3 | 0 | 0 | 0 | 1 | 4 | 0 | 1 post or article, 1 podcast or video, 1 registry |
| F10 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 1 post or article, 1 publication |

### Trial dimensions

- Primary endpoint: Percentage of Participants With Adverse Events (AE): F1 (4 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (3 shared claims)
- Primary endpoint: Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706: no finding draws on it directly
- Primary endpoint: Time to Cmax (Tmax) of ABBV-706: no finding draws on it directly
- Primary endpoint: Terminal Phase Elimination Half-Life (t1/2) of ABBV-706: no finding draws on it directly
- Primary endpoint: Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706: no finding draws on it directly
- Primary endpoint: Antidrug Antibodies (ADAs): no finding draws on it directly
- Primary endpoint: Neutralizing Antibodies (nAbs): no finding draws on it directly
- Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors: F1 (3 shared claims), F2 (8 shared claims), F3 (2 shared claims), F4 (4 shared claims), F5 (1 shared claims), F6 (4 shared claims)
- Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706: F1 (2 shared claims), F3 (4 shared claims), F4 (1 shared claims)
- Primary endpoint: Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors: no finding draws on it directly
- Primary endpoint: Duration of response (DOR) for Participants with Confirmed CR/PR: F2 (1 shared claims)
- Primary endpoint: Percentage of Participants with Clinical Benefit: no finding draws on it directly
- Primary endpoint: Progression-Free Survival (PFS): F1 (1 shared claims), F2 (2 shared claims), F4 (2 shared claims), F5 (2 shared claims)
- Primary endpoint: Overall survival (OS): F1 (1 shared claims), F2 (5 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (2 shared claims)
- Population and setting: F2 (4 shared claims), F6 (7 shared claims), F7 (1 shared claims), F8 (1 shared claims)
- The comparison: F1 (4 shared claims), F2 (2 shared claims), F3 (3 shared claims), F4 (4 shared claims)
- Safety and tolerability: F1 (4 shared claims), F2 (1 shared claims), F3 (3 shared claims), F4 (3 shared claims)
- Design and conduct: F1 (2 shared claims), F2 (3 shared claims), F3 (1 shared claims), F4 (1 shared claims), F6 (1 shared claims)

## Abbreviations

- AE: adverse event
- CNS: central nervous system
- CR: complete response
- DOR: duration of response
- HCP: healthcare professional
- ILD: interstitial lung disease
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate
- OS: overall survival
- PFS: progression-free survival
- PR: partial response
- RP2D: recommended phase 2 dose
- RT: radiotherapy
- SCLC: small cell lung cancer

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 69 | Paid |
| Who said each statement: the cited speakers | 14 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 11 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 14 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 23 | Free |
| Sources with links | 20 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 11 of the 14 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

15 discussed · 8 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Percentage of Participants With Adverse Events (AE) | discussed | 6 | 3 |
| Primary endpoint: Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706 | no commentary found | 0 | 0 |
| Primary endpoint: Time to Cmax (Tmax) of ABBV-706 | no commentary found | 0 | 0 |
| Primary endpoint: Terminal Phase Elimination Half-Life (t1/2) of ABBV-706 | no commentary found | 0 | 0 |
| Primary endpoint: Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706 | no commentary found | 0 | 0 |
| Primary endpoint: Antidrug Antibodies (ADAs) | no commentary found | 0 | 0 |
| Primary endpoint: Neutralizing Antibodies (nAbs) | no commentary found | 0 | 0 |
| Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors | discussed | 16 | 10 |
| Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706 | discussed | 5 | 2 |
| Primary endpoint: Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors | no commentary found | 0 | 0 |
| Primary endpoint: Duration of response (DOR) for Participants with Confirmed CR/PR | discussed | 1 | 1 |
| Primary endpoint: Percentage of Participants with Clinical Benefit | no commentary found | 0 | 0 |
| Primary endpoint: Progression-Free Survival (PFS) | discussed | 4 | 4 |
| Primary endpoint: Overall survival (OS) | discussed | 7 | 6 |
| Population and setting | discussed | 11 | 4 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 8 | 3 |
| Safety and tolerability | discussed | 7 | 4 |
| Design and conduct | discussed | 5 | 3 |
| SEZ6 rationale, perceived promise and reactions to dissemination | discussed | 9 | 7 |
| Patient-selection hypotheses and exploratory biomarkers | discussed | 4 | 4 |
| Confirmatory development and a proposed post-tarlatamab sequence | discussed | 3 | 2 |
| Prospective trial access and patient-support implications | discussed | 3 | 2 |
| Symptomatic brain metastases: local therapy versus tarlatamab | discussed | 1 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 20 statements · 29%** | | | |
| YouTube | 20 | 1 | 1 |
| **Posts · 22 statements · 32%** | | | |
| X threads | 22 | 17 | 27 |
| Bluesky threads | 0 | 0 | 1 |
| **Primary sources · 27 statements · 39%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 26 | 1 | not screened |
| Registry (primary source, cited for context) | 1 | 1 | not screened |

- Screened window: 2023-04-07 to 2026-11-13
- Cited window: 2023-04-07 to 2026-11-13
- Retrieved: 2026-11-21

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
- Registry: NCT05599984 (https://clinicaltrials.gov/study/NCT05599984)
- Study IDs: M23-385 · 2023-504598-18-00
- Sponsor: AbbVie
- Design: Phase 1 · interventional, non randomized, sequential, phase1
- Status: Active, not recruiting
- Enrollment: 288 (actual)
- Start: 2022-12-05 (actual)
- Primary completion: 2027-11 (estimated)
- Primary endpoint: Percentage of Participants With Adverse Events (AE) (Up to Approximately 2 Years)
- Primary endpoint: Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706 (Up to Approximately 2 Years)
- Primary endpoint: Time to Cmax (Tmax) of ABBV-706 (Up to Approximately 2 Years)
- Primary endpoint: Terminal Phase Elimination Half-Life (t1/2) of ABBV-706 (Up to Approximately 2 Years)
- Primary endpoint: Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706 (Up to Approximately 2 Years)
- Primary endpoint: Antidrug Antibodies (ADAs) (Up to Approximately 2 Years)
- Primary endpoint: Neutralizing Antibodies (nAbs) (Up to Approximately 2 Years)
- Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors (Up to Approximately 2 Years)
- Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706 (Up to Approximately 2 Years)
- Primary endpoint: Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors (Up to Approximately 2 Years)
- Primary endpoint: Duration of response (DOR) for Participants with Confirmed CR/PR (Up to Approximately 2 Years)
- Primary endpoint: Percentage of Participants with Clinical Benefit (Up to Approximately 2 Years)
- Primary endpoint: Progression-Free Survival (PFS) (Up to Approximately 2 Years)
- Primary endpoint: Overall survival (OS) (Up to Approximately 2 Years)
- Intervention: ABBV-706 (drug)
- Intervention: Cisplatin (drug)
- Intervention: Budigalimab (drug)
- Intervention: Carboplatin (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on uncertain cohort attribution of the treatment-related mortality statement.
- 15 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 17 sources about other trials or topics are not included.
- Many commentary passages identify ABBV-706 and a relevant setting rather than NCT05599984. Their clinical relevance does not make every numerical summary an independently identified result of this trial.
- The linked publication describes preliminary phase 1 efficacy without a standard-of-care comparator or efficacy hypothesis testing. It separately describes a randomized dose-optimization component.
- Safety summaries use different populations and adverse-event categories. Small combination-cohort reassurance cannot be generalized to monotherapy, and all reported safety figures cannot be reconciled from these statements.
- Repeated posts, reposts and presentation relays are not independent clinical appraisals. A favorable publication reaction is not necessarily an efficacy or practice-adoption judgment.
- Intracranial efficacy, validated patient-selection biomarkers and efficacy after tarlatamab remain incompletely addressed.
- No separate protocol or exact product labels for ABBV-706 or budigalimab were available in the sources reviewed; this report does not establish regulatory status or approved-use boundaries.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-21 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-21 UTC. No changes.

## Offer

- Size: Focused · 69 verified statements · 37 from 11 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (14 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/m23-385-nct05599984
- Agents: POST https://www.erudio.com/api/orders with {"report": "m23-385-nct05599984", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=m23-385-nct05599984

## Cite

Erudio Health. M23-385 (NCT05599984): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/m23-385-nct05599984

## Questions

### How much does the M23-385 report cost?

One edition costs $750 (Focused · 69 verified statements · 37 from 11 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the M23-385 report cover?

69 statements from 20 sources (1 video, 17 posts, 1 paper, 1 registry record), 37 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the M23-385 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "m23-385-nct05599984" }) previews it and create_order({ "report": "m23-385-nct05599984", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the M23-385 report?

Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/m23-385-nct05599984.json
- Markdown: https://www.erudio.com/reports/m23-385-nct05599984.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/m23-385-nct05599984/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "m23-385-nct05599984"}`
